Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch

Published 23/05/2022, 17:31
© Reuters.  Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch

The Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) gapped up almost 2.52% higher on Monday in response to outbreaks of monkeypox being reported in several western nations.

CURE is a triple leveraged fund that is designed to outperform 72 U.S. companies in the home health care sector. The index includes a variety of companies including biotechnology, pharmaceuticals, health care equipment, supplies and technology developers and suppliers.

Some of the more familiar names in the ETF include Johnson & Johnson (NYSE: JNJ), weighted at 7.03%; Pfizer Inc. (NYSE: NYSE:PFE), weighted at 4.36%; and Thermo Fisher Scientific Inc. (NYSE: NYSE:TMO), weighted at 3.33%.

It should be noted that leveraged ETFs are meant to be used as a trading vehicle as opposed to a long-term investment.

Want direct analysis? Find me in the BZ Pro lounge! Click here for a free trial.

The CURE Chart: CURE reversed course into an uptrend after printing a bullish double bottom pattern on Feb. 24 and May 12 at the $97.67 level. The uptrend on CURE’s chart was confirmed on May 19, when the ETF printed a higher low at $100.18.

  • On Monday, CURE was attempting to work to rise up to print a higher high above the May 17 high of $112.58. Bullish traders and investors will want to see that happen before CURE makes another low, which would negate the uptrend.
  • CURE regained the support of the 21-day exponential moving average (EMA) on Monday, which is a positive sign for the bulls. When the ETF prints its last high it rejected the 21-day, which caused CURE to fall over 10% to print its higher low.
  • If CURE can remain trading above the 21-day EMA for a period of time, the eight-day EMA will cross above the 21-day, which would give bullish traders more confidence going forward. The 50-day simple moving average (SMA) hasn’t crossed below the 200-day SMA yet, which means CURE has, so far, avoided a death cross from occurring on its chart.
  • If CURE closes the trading day near its high-of-day price, it’s likely the ETF will trade higher on Tuesday to print a higher high. If the ETF closes flat or near its low-of-day price, CURE will print a doji candlestick or shooting star candlestick, respectively, which could indicate lower prices are on the horizon.
  • CURE has resistance above at $112.71 and $118.60 and support below at $105.30 and $97.67.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.